grant
Human papillomavirus and risk to pregnancy: a cohort study
Organization UNIVERSITY OF TEXAS MED BR GALVESTONLocation GALVESTON, UNITED STATESPosted 4 Sept 2025Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY202537 weeks completed gestation37 weeks gestation3rd trimesterAddressAmniotic FluidAqua AmniiAreaBiologicalC trachomatisC. trachomatisCancersCells Placenta-TissueCervicalCervical CancerCervixCervix CancerCervix UteriChlamydiaChlamydia trachomatisClinicClinicalCohort StudiesConcurrent StudiesConfounding Factors (Epidemiology)Confounding VariablesCytologyDNADataDeoxyribonucleic AcidDetectionDisease ProgressionEnsureEpidemiologic Confounding FactorEvaluationFutureGenotypeGestationHPVHPV [-]HPV infectionHPV negativeHPV screeningHPV(-)HPV-High RiskHeterogeneityHigh Risk Oncogenic HPVHigh risk HPVHigh risk Human PapillomavirusHigh risk Human papilloma virusHuman Papilloma VirusHuman Papilloma Virus screeningHuman PapillomavirusHuman papilloma virus infectionHuman papillomavirus infectionHypertension-Associated Pregnancy DisorderImmune responseInfantInfant MortalityInfant Mortality TotalInfectionInfectious Human Wart VirusInvestigationKnowledgeLast TrimesterLinkLiquor AmniiLiteratureLong-term infectionMalignant Cervical NeoplasmMalignant Cervical TumorMalignant Neoplasm of the CervixMalignant NeoplasmsMalignant TumorMalignant Tumor of the CervixMalignant Tumor of the Cervix UteriMalignant Uterine Cervix NeoplasmMalignant Uterine Cervix TumorMalignant neoplasm of cervix uteriMeasurementMeasuresMedicalMeta-AnalysisMethodologyMiyagawanellaNational Institutes of HealthNormal PlacentomaOutcomePathologyPlacentaPlacenta Embryonic TissuePlacentomePregnancyPregnancy ComplicationsPremature BirthPrematurely deliveringPrenatal carePreterm BirthPrevalenceProspective StudiesProspective cohortProspective, cohort studyPublic HealthReportingResearchResearch DesignRetrospective StudiesRickettsia trachomaeRiskRisk FactorsRisk-associated variantSamplingSexually Transmitted DiseasesSexually Transmitted DisorderSexually Transmitted InfectionStrategic PlanningStudy TypeSwabTestingTexasThird Pregnancy TrimesterThird TrimesterTimeUnited States National Institutes of HealthUniversitiesUrineUterine CervixUterine Cervix CancerVaginaVaginal HPVVaginal Human Papilloma VirusVaginal Human PapillomavirusVenereal DiseasesVenereal DisordersVenereal InfectionsViralabsence of HPVabsence of human papillomavirusadverse pregnancy outcomeafter pregnancybedsoniabiologiccancer riskchronic infectionclinical riskco-infectioncoinfectioncomplications during pregnancycondylomadeath among infantsdeath in first year of lifedeath in infancydeath in infantsdetection sensitivityearly in pregnancyearly pregnanciesearly pregnancyearly stage of pregnancyfield based datafield learningfield studyfield testhigh riskhost responsehrHPVhuman papillomavirus negativehypertensive disease during pregnancyhypertensive disease in pregnancyhypertensive disease of pregnancyhypertensive disorder during pregnancyhypertensive disorder in pregnancyhypertensive disorder of pregnancyimmune system responseimmunoresponseimprovedinfant deathinfant demiseinfantile deathmalignancymortality in infantsmultidisciplinaryneoplasm/cancernovelpersistent infectionpopulation healthpost pregnancypregnancy carepregnancy induced hypertensive disorderpregnancy related hypertensive diseasepregnancy-related complicationspregnancy-specific hypertensive disorderpremature childbirthpremature deliveryprenatalprenatal appointmentprenatal checkupprenatal screeningprenatal testingprenatal visitpreterm deliveryprospectiverisk allelerisk generisk genotyperisk locirisk locusrisk variantsexually acquired infectionstudy designsuccessunbornwart virus
Description preview
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI), and a major concern as high-risk genotypes cause cervical and other cancers. Beyond cancer risk, there is growing evidence that HPV may be associated with adverse pregnancy outcomes. Indeed, studies show that HPV is highly prevalent during pregnancy, can infect the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click